Zacks Research Estimates McKesson’s Q2 Earnings (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Zacks Research reduced their Q2 2026 EPS estimates for McKesson in a research note issued on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $8.39 for the quarter, down from their prior estimate of $8.51. The consensus estimate for McKesson’s current full-year earnings is $32.07 per share. Zacks Research also issued estimates for McKesson’s FY2026 earnings at $35.05 EPS, Q1 2027 earnings at $8.03 EPS, Q2 2027 earnings at $9.04 EPS and FY2027 earnings at $40.21 EPS.

Other equities analysts also recently issued research reports about the company. Citigroup cut their target price on McKesson from $670.00 to $630.00 and set a “buy” rating on the stock in a research report on Tuesday, September 10th. Mizuho increased their target price on shares of McKesson from $540.00 to $570.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. lifted their price target on shares of McKesson from $656.00 to $661.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Robert W. Baird reissued a “neutral” rating and issued a $531.00 price objective (down from $603.00) on shares of McKesson in a research report on Tuesday, September 24th. Finally, StockNews.com cut McKesson from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $610.86.

McKesson Trading Up 0.6 %

MCK opened at $504.96 on Friday. McKesson has a 12 month low of $431.35 and a 12 month high of $637.51. The stock has a 50-day moving average of $518.29 and a 200 day moving average of $551.37. The firm has a market cap of $65.61 billion, a P/E ratio of 22.56, a P/E/G ratio of 1.17 and a beta of 0.44.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, topping analysts’ consensus estimates of $7.21 by $0.67. The business had revenue of $79.28 billion during the quarter, compared to analysts’ expectations of $82.53 billion. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The business’s revenue was up 6.4% on a year-over-year basis. During the same period last year, the company posted $7.27 EPS.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 1st. Shareholders of record on Monday, September 2nd were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 0.56%. This is a boost from McKesson’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, August 30th. McKesson’s dividend payout ratio is currently 12.69%.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 3,753 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $561.10, for a total value of $2,105,808.30. Following the completion of the sale, the chief executive officer now directly owns 78,586 shares of the company’s stock, valued at $44,094,604.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.11% of the company’s stock.

Institutional Trading of McKesson

A number of hedge funds have recently bought and sold shares of the stock. Distillate Capital Partners LLC raised its position in shares of McKesson by 127,542.9% in the 2nd quarter. Distillate Capital Partners LLC now owns 35,740 shares of the company’s stock worth $20,874,000 after acquiring an additional 35,712 shares in the last quarter. Chase Investment Counsel Corp lifted its position in shares of McKesson by 50.8% during the second quarter. Chase Investment Counsel Corp now owns 8,985 shares of the company’s stock valued at $5,247,000 after buying an additional 3,027 shares during the last quarter. Wealthspire Advisors LLC boosted its holdings in shares of McKesson by 8.9% in the 2nd quarter. Wealthspire Advisors LLC now owns 1,623 shares of the company’s stock valued at $948,000 after buying an additional 133 shares in the last quarter. Councilmark Asset Management LLC bought a new stake in shares of McKesson in the 1st quarter valued at about $5,160,000. Finally, Vaughan David Investments LLC IL purchased a new position in shares of McKesson in the 2nd quarter worth approximately $238,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.